RxDoctor Payments Data

Nauman Imami, MD

Ophthalmology · Detroit, MINPI 1649330044

Payments from drug & device makers

$2,099in general payments, 2019–2025

Across 18 payments — averaging $116.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$1K
  • Alcon$466
  • NEW World Medical,inc.$280
  • AbbVie$214
  • Aerie Pharmaceuticals, Inc.$100
  • Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$24
  • plus $15 from 1 others

What the payments were for

  • Speaking & faculty fees$1,00048%
  • Food & beverage$1,09952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,099 in reported general payments places this provider in the 60th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$64,300
Medicare patients
287
Services billed
1,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Brimonidine Tartrate508$84,327
RhopressaNetarsudil Mesylate85$42,480
LumiganBimatoprost57$24,662
Latanoprost1,638$22,748
VyzultaLatanoprostene Bunod53$20,579
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat626$18,305
Brinzolamide74$16,467
Methazolamide39$14,786
Timolol Maleate275$9,555
Alphagan PBrimonidine Tartrate12$7,171
CombiganBrimonidine Tartrate/Timolol12$6,364
TafluprostTafluprost/Pf31$5,713
RocklatanNetarsudil Mesylat/Latanoprost17$5,679
Prednisolone Acetate77$4,739
Travatan ZTravoprost12$4,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$100$48,160102 claims
AbbVieLumigan, Alphagan P, Combigan$214$38,19781 claims
Bausch & Lomb Americas Inc.Vyzulta$1,000$20,57953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →